A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children. The project, developed by the University of Trento, Bambino Gesù Children's Hospital and Sapienza University of Rome, is a breakthrough in the study, understanding and treatment of the disease.

A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease. Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults.

Fans of Korean skincare may be familiar with ‘hero ingredient’ Madecassic acid for its skin-soothing properties, but researchers at the University of Kent have revealed its greater potential for use in the battle against antibiotic resistance. Using a combination of computational screening and laboratory experiments, scientists in the School of Natural Sciences together with those at University College London (UCL) have demonstrated how this natural chemical from the common Asian herb Centella asiatica, is an effective antibacterial drug.

Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, announced the evolution of Standing in the Gaap, a long-running program designed to help address persistent gaps in care for people living with multiple myeloma (MM) in medically underserved communities. Building on a decade of sustained commitment, BMS is reinforcing its focus on equitable access to multiple myeloma education, resources, and community-driven solutions by expanding the program to reach more patients and care partners.